Choline Salicylate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Choline Salicylate: From Analgesic/Anti-inflammatory Use to Prinzmetal Angina
One-Sentence Summary
Choline salicylate is a salicylate-class compound with analgesic and anti-inflammatory properties, related to aspirin in its pharmacological mechanism. The TxGNN model predicts it may be effective for Prinzmetal Angina (variant angina due to coronary vasospasm), with 0 clinical trials and 0 publications directly supporting this indication — evidence currently rests at the mechanistic hypothesis stage only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not registered in India; salicylate-class analgesic/anti-inflammatory (class-level knowledge) |
| Predicted New Indication | Prinzmetal Angina |
| TxGNN Prediction Score | 99.84% |
| Evidence Level | L4 |
| India Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known pharmacological knowledge, choline salicylate is a choline salt of salicylic acid — a member of the same drug family as aspirin. Like other salicylates, it exerts analgesic, antipyretic, and anti-inflammatory effects primarily through cyclooxygenase (COX) inhibition. The choline salt formulation is thought to produce less gastrointestinal mucosal irritation compared to acetylsalicylic acid, which gives it a theoretical tolerability advantage.
The proposed mechanistic link to Prinzmetal angina relies on COX-1 inhibition reducing thromboxane A2 (TXA2) — a potent coronary vasoconstrictor and platelet aggregator. Lower TXA2 levels could theoretically attenuate the vasospasm episodes that define Prinzmetal angina. This reasoning parallels the well-established use of low-dose aspirin in atherothrombotic cardiovascular disease, where antiplatelet effects are the primary benefit.
However, this rationale carries significant caveats. High-dose salicylate therapy simultaneously suppresses prostacyclin (PGI2) — a natural vasodilator — which could offset or reverse any vasodilatory benefit. More importantly, all relevant cardiovascular evidence derives from aspirin studies; there is no direct research on choline salicylate in coronary vasospasm. The TxGNN prediction is mechanistically plausible but remains purely theoretical at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Choline salicylate is currently not registered or marketed in India. No authorization records are available in the regulatory database.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN confidence score (99.84%), there are zero clinical trials and zero publications directly investigating choline salicylate in Prinzmetal angina. Combined with no India regulatory history, absent safety documentation, and a mechanism inferred entirely from aspirin class-effect data rather than from the compound itself, the evidence base does not support moving forward at this time.
To proceed, the following is needed:
- MOA verification: Retrieve choline salicylate mechanism of action from DrugBank API (DB14006) to confirm COX pathway relevance
- Safety package: Download and parse the CDSCO / FDA package insert for key warnings, contraindications, and drug interaction profile — currently a blocking data gap (DG001)
- Salicylate class literature review: Search specifically for aspirin or salicylate use in Prinzmetal angina / coronary vasospasm as a class-effect reference point before investing in choline salicylate-specific research
- PK/PD feasibility: Assess whether oral choline salicylate achieves plasma concentrations sufficient for cardiovascular COX-1 inhibition, since current formulations are primarily used for local analgesic effects
- Regulatory pathway scoping: Given zero India registrations, evaluate whether any global reference market (EU, US, Japan) has approved choline salicylate for a cardiovascular indication before initiating repurposing activities
- Consider rank 2 (Rheumatoid Arthritis) as a higher-priority target: The RA indication has stronger historical and mechanistic grounding — salicylates were the standard RA treatment before DMARDs — and may present a more tractable starting point for a Choline salicylate repurposing program
⚠️ Disclaimer: This report is for research reference only and does not constitute medical advice. All drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.